Osiris Therapeutics News

During the last five days Osiris Therapeutics posted a 20% gain following exciting news .

There is great news for parents suffering the harrowing ordeal of their child needing a bone marrow transplant.

Autodesk, Inc. A : Although software developer Autodesk reported in-line first quarter earnings per share, it is showing weakness in some locations.

Foot Locker opened at $31.64 after closing the previous trading session at $28.01, gapping up.

Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy ProchymalA , for the treatment of acute graft-vs-host disease in children.

GXS of Gaithersburg, which provides business computer integration services, reported that its first-quarter net loss widened to $4.6 million from $3.8 million in the prior-year quarter.

Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy ProchymalA , for the treatment of acute graft-vs-host disease in children.

Osiris Therapeutics has received marketing approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children.

The Columbia stem cell developer posted a loss of nearly $1.3 million, or 4 cents per share, during the quarter.

COLUMBIA, Md. -- -- Osiris Therapeutics, Inc. , the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today its results for the first quarter ended March 31, 2012.